The landscape of dementia prognosis has advanced significantly with the appearance of subtle biomarkers, which includes amyloid PET scans, tau imaging, and blood-primarily based exams that will detect Alzheimer's pathology decades just before symptoms emerge. While these technological improvements depict remarkable progress in being familiar with n